Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Oncotherapeutics
OBJECTIVES: Primary * To determine the response rate (i.e., complete response, very good partial response , partial response, and minimal response) in patients with newly diagnosed multiple myeloma treated with pegylated liposomal doxorubicin hydrochloride, bortezomib, and dexamethasone. Secondary * To assess the safety and tolerability of this regimen in these patients. * To determine the time to disease progression, time to response, duration of response, progression-free survival, and overall survival of patients treated with this regimen. OUTLINE: Patients receive pegylated liposomal doxorubicin hydrochloride IV over 30-90 minutes, dexamethasone IV, and bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Blood and urine samples are collected at baseline and periodically during study for M-protein analysis by electrophoresis and immunofixation. After completion of study therapy, patients are followed periodically.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
